News & Events
Yes. The AMA announced the creation of two new codes 91309 and 0094A that describe Moderna’s new 50 mcg/0.5 mL booster dose-specific COVID-19 vaccine vial. Code 91309 is the product code and 0094A is its associated administration code. These two codes are reported...
News & Events
Yes. EVUSHELD is a combination product of tixagebimab and cilgavimab that is used as a pre-exposure prophylactic treatment for COVID-19. On March 10, 2022, CMS announced the creation of new HCPCS code Q0221 to represent the recently authorized higher dosage of...
News & Events
Yes. On February 11, 2022, the FDA authorized emergency use of bebtelovimab for treatment of mild-to-moderate COVID-19 in certain adult and pediatric patients who are at high risk for progression to severe COVID-19, including hospitalization or death, when: The...
News & Events
Yes. CMS announced the creation of new HCPCS code, C9507, to report on outpatient claims for convalescent plasma treatment for COVID-19 patients with immunosuppressive challenges. For your convenience, the long and short code descriptors for HCPCS C9507 are listed...
News & Events
Yes. On January 3, 2022, the FDA updated the emergency use authorization for the Pfizer pediatric COVID-19 vaccine (orange cap) to allow for third doses for certain immunocompromised children ages 5 through 11. It is important to highlight these are not booster doses...
News & Events
Yes. Coverage for remdesivir has been evolving and changing quickly over the past few weeks. Initially, CMS announced the creation of code J0248 (Injection, remdesivir, 1 mg) with an effective date of December 23, 2021. However, at the time the FDA had not yet...
